共 73 条
Montelukast in guidelines and beyond
被引:21
作者:
Bousquet, Jean
[1
]
Demoly, Pascal
[1
,2
]
Humbert, Marc
[3
]
机构:
[1] Hop Arnaud Villeneuve, Serv Malad Resp, F-34275 Montpellier 5, France
[2] INSERM, U657, F-75654 Paris 13, France
[3] Univ Paris 11, Hop Antoine Beclere, Clamart, France
关键词:
allergic rhinitis;
asthma;
guidelines;
inhaled corticosteroids;
montelukast;
rhinitis;
LEUKOTRIENE-RECEPTOR ANTAGONIST;
SEASONAL ALLERGIC RHINITIS;
TERM CLINICAL-TRIAL;
INHALED CORTICOSTEROIDS;
ASTHMA CONTROL;
DOUBLE-BLIND;
PRESCHOOL-CHILDREN;
ORAL MONTELUKAST;
MILD ASTHMA;
PLACEBO;
D O I:
10.1007/s12325-009-0038-1
中图分类号:
R-3 [医学研究方法];
R3 [基础医学];
学科分类号:
1001 ;
摘要:
In all asthma guidelines, preventive anti-inflammatory treatment is essential in all patients with persistent asthma. Inhaled corticosteroids are the mainstay of treatment in the control of asthma, but other treatments may be used as a monotherapy in patients with mild asthma or as an add-on treatment in those with moderate-to-severe asthma. Leukotriene modifiers are the only validated preventive treatment for all age groups. This review discusses the place of montelukast, a leukotriene receptor antagonist, using guidelines and consensus reports on asthma and rhinitis: the US National Asthma Education and Prevention Program (NAEPP); the British Guideline on the Management of Asthma; the Global Initiative on Asthma (GINA); and Allergic Rhinitis and its Impact on Asthma (ARIA). This review includes new studies that have not yet been considered in guidelines.
引用
收藏
页码:575 / 587
页数:13
相关论文